Biotech Startups

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance. It focuses on improving treatment outcomes for patients living with breast cancer.

6 investors

Olio Labs develops drug combination therapies using machine learning to identify treatments that target multiple interacting proteins simultaneously, with initial candidates focused on obesity treatment. The company aims to create pharmaceutical solutions that achieve greater efficacy and lower side effect profiles than existing single-target medications.

6 investors

San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.

6 investors

On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology. It operates in the biotech and medtech space.

6 investors

ONI develops the Nanoimager, an automated super-resolution imaging system. The company serves researchers and laboratories in life sciences and microscopy applications.

6 investors

Oobli develops sweet proteins derived from equatorial fruits and berries, using a fermentation process to produce a sugar alternative that is thousands of times sweeter than sugar. The company creates consumer products made with these fermentation-produced sweet proteins as a healthier form of sweetness.

6 investors

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance. Its pipeline includes rinzimetostat (ORIC-944) in Phase 1b for prostate cancer and enozertinib (ORIC-114) in Phase 1b for non-small cell lung cancer with EGFR mutations.

6 investors

Orionis Biosciences discovers and engineers molecules that connect proteins on or within cells to reprogram disease-driving processes or activate immune responses. It develops therapeutics for cancer, autoimmune diseases, and neurodegenerative disorders through collaborations with industry and academic institutions.

6 investors

Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms. The company builds programmable immunotherapies targeting cancer patients.

6 investors

Owkin develops AI Scientist, an autonomous AI system that uses biological large language models and multimodal patient data to accelerate drug discovery for pharmaceutical and biotech companies. The company aims to automate early-stage R&D and compress decades of discovery timelines into years.

6 investors

Pangea Bio develops therapies targeting central nervous system and mental health disorders by activating the TrkB receptor pathway to promote neuronal survival and synaptic plasticity. The company serves patients with neurological and mental health conditions.

6 investors

Paradigm Health provides technology and services that integrate with healthcare provider organizations to improve the clinical trial process. It works with providers and sponsors to increase patient enrollment and expand patient access to clinical trials.

6 investors

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

6 investors

Pencil Biosciences develops a fully synthetic, modular, non-CRISPR gene editing platform that edits DNA without causing a break or nick. The technology targets applications in therapeutics and cell line engineering.

6 investors

Perfect Day produces animal-free milk protein made through fermentation (from flora) to replicate dairy proteins without cows, supplying brands that make products such as ice cream. The company serves the food and consumer goods industry with sustainable dairy alternatives.

6 investors

Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms. The company focuses on advancing therapeutic programs from preclinical development through clinical stages.

6 investors

Phagos develops phage therapy treatments as an alternative to antibiotics, using its Alphagos platform that combines microbiology and AI to design targeted bacterial medicines against antimicrobial resistance. Its treatments are deployed across animal agriculture sectors including chicken, cattle, swine, and shrimp.

6 investors

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema. It is a clinical-stage biopharmaceutical company focused on this rare disease area.

6 investors

Phylo is an applied research lab studying agentic AI to accelerate biomedical discoveries for scientists. The company develops AI agents designed to advance how biomedical research is conducted.

6 investors

Phytoform Labs develops GM-free genome editing tools and trait engineering technologies for crop improvement, with a focus on potato and tomato varieties. The company works at the intersection of biotechnology and agricultural research to advance sustainable crop breeding.

6 investors

PMV Pharma is a precision oncology company developing therapies that selectively target mutant p53 to treat cancers whose tumors carry p53 gene mutations. Its lead program is rezatapopt, a reactivator of the p53 Y220C mutation in clinical trials.

6 investors

Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.

6 investors

Promakhos Therapeutics develops immunomodulatory therapies to restore immune system balance and reduce chronic inflammation in diseases like Crohn's disease, ankylosing spondylitis, and psoriasis. The company targets patients with inflammatory diseases who do not benefit from current immunosuppressive treatments.

6 investors

Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery. The company operates in the medical device industry, serving pulmonologists and patients with severe emphysema through a minimally invasive lung treatment.

6 investors